Today: October 23, 2018, 5:40 am
  
Business

Bavarian Nordic to Host First Quarter 2018 Results Conference Call

PR-Inside.com: 2018-05-16 17:32:02

COPENHAGEN, Denmark - May 16, 2018 - Bavarian Nordic A/S (OMX:  BAVA, OTC: BVNRY) will announce its 2018 first quarter results on Thursday, May 24, 2018.

The management of Bavarian Nordic will host a conference call at 2:00 pm CEST (8:00 am EDT) on the same day to present the interim results followed by a Q&A session. A live and replay version of the call and relevant slides will be available at http://bit.ly/2KzQlN2.

To join the Q&A session dial one of the following numbers and state the participant code 8332812: Denmark: +45 35 15 81 21, UK: +44 (0) 330 336 9411, USA: +1 323-794-2551.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Phone +45 61 77 47 43
U.S.: Seth Lewis, Vice President, Investor Relations & Communications. Phone: +1 978 341 5271

About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the development of innovative and safe therapies against cancer and infectious diseases. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates intended to improve the health and quality of life for children and adults. We supply our IMVAMUNE® non-replicating smallpox vaccine to the U.S. Strategic National Stockpile and other government stockpiles. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Registration studies are currently underway in the U.S. In addition to our long-standing collaboration with the U.S. government on the development of IMVAMUNE® and other medical countermeasures, our infectious disease pipeline comprises a proprietary RSV program as well as vaccine candidates for Ebola, HPV, HBV and HIV, which are developed through a strategic partnership with Janssen. Additionally, in collaboration with the National Cancer Institute, we have developed a portfolio of active cancer immunotherapies, designed to alter the disease course by eliciting a robust and broad anti-cancer immune response while maintaining a favorable risk-benefit profile. Through multiple industry collaborations, we seek to explore the potential synergies of combining our immunotherapies with other immune-modulating agents, e.g. checkpoint inhibitors.

For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via Globenewswire




# 552 Words
Related Articles
More From The Author
Olvi:SHARE REPURCHASE 16.5.2018
Olvi PlcStock Exchange Release16.5.2018      SHARE REPURCHASE  16.5.2018     In the NASDAQ OMX Helsinki     Trade date 16.5.2018 Bourse [..]
Banks net position in the Riksbank
MAY 16, 2018 SEK MILLION   LENDINGBORROWING144   
Digi Communications NV Announces the Availability of [..]
We would like to inform our shareholders and the market that the Company has made available the detailed instructions regarding [..]
MakeMyTrip Limited to Report Fiscal 2018 Fourth [..]
New Delhi and New York, May 16, 2018 MakeMyTrip Limited (Nasdaq:MMYT), India's leading online travel company, plans to [..]
Medtronic Begins U.S. Study of Drug-Eluting Stents [..]
Medtronic Received IDE Approval from FDA to Generate Clinical Evidence with Resolute Onyx DES to Support Future Application for [..]
 
More From Business
Buy LoL Smurfs Will Help You Find [..]
17 October 2018 – Buy LoL Smurfs is offering the one of a kind opportunity to buy league of legends [..]
Swiss Watches from the Best Online Shop [..]
22th October 2018 - Luxury Replica provides totally amazing products from Swiss. Swiss watches, the syntagm which breaks stereotypes [..]
Integra Certified Document Destruction Achieves Certification
ELKHART, INDIANA, UNITED STATES - October 11th, 2018 - Integra Certified Document Destruction(“Integra”) is proud to announce [..]
11th Asian Downstream Summit: Digital Transformation Awards [..]
SINGAPORE, Oct 10, 2018 - (ACN Newswire) - Voting for Asian Downstream Summit: Digital Transformation Awards 2018 has opened. The [..]
Indonesian Minister of SOEs officially closes 2018 [..]
Surabaya, East Java, Indonesia, Oct 9, 2018 - (ACN Newswire) - Minister of State-Owned Enterprises (SOEs) of Republic of Indonesia [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.